Stay informed on developments in cancer and oncology diagnosis, prevention and treatment through these curated webinars. As the race toward a cure for cancer continues, advances in cancer research are constantly revealed as innovation in the field of oncology progresses.
The future of cancer care is contingent on better understanding of molecular, clinical, and outcome data. This can be achieved by leveraging collaborative affiliations and networks locally a...
Discover how experience in utilizing a digital lab platform can elevate research workflows. Margriet will share insights, practical strategies, and success stories that demonstrate the benef...
Key to precision oncology is the development of expert databases that organize and standardize information on cancer-related genetic variants, as well as their associated diagnostic, prognos...
Racial and ethnic minorities often experience cancer disparities in the United States with higher disease prevalence, shorter survival, and higher death rates with many cancer types. These d...
Technological advances in Artificial Intelligence (AI), particularly deep learning, have demonstrated remarkable progress in image-recognition tasks. Methods ranging from convolutional neura...
One of the central tenants of biology is that our genetics—our genotype—influences the physical characteristics we manifest—our phenotype. But with more than 25,000 human g...
In the United States, cancer disproportionately impacts Black and African American individuals. Identifying genetic factors underlying cancer disparities has been an important research focus...
Bromodomains (BRDs) are evolutionarily conserved protein domains that interact with acetylated histones and set off a chain of events that includes recruiting transcription factors and other...
Genomic research has long been skewed toward European populations, leading to significant underrepresentation of Non-European groups in both research studies and genomic databases. This bias...
Jeff Borgia, Ph.D. is the Director of the Rush Cancer Center Biorepository, where he oversees the collection and annotation of patient specimens in support of ongoing translational research...
Immuno-oncology (IO) is a type of cancer treatment that uses the body's immune system to fight cancer. It works by stimulating the immune system to recognize and attack cancer cells, while le...
The majority of disease-associated genetic variants are thought to have regulatory effects, including disruption of transcription factor (TF) binding and alteration of downstream gene expres...
The ultimate promise of tumor immunotherapy is dependent on the generation of effective immunity against cancer, including CD4 and CD8 T cell responses. However, activating T cells in cancer...
Individuals with Lynch syndrome (LS) are prone to develop early-onset mismatch repair deficient (dMMR) colorectal- and endometrial cancers due to germline pathogenic variants (PVs) in one of...
Uterine leiomyosarcoma (uLMS) is a rare aggressive sarcoma of the smooth muscle layer of the uterus manifested in high local recurrence and metastatic rate. Currently, effective treatment of...
Learning Objectives: 1. Explain how obesity impacts the survival of pediatric patients with specific subtypes of leukemia. 2. Describe how obesity impacts T-cell function in pediatric popula...
The microenvironment of many solid tumors impedes many immunotherapeutic treatments by inhibiting the effector functions of many classes of anti-tumor immune cells, including effector T cell...
Despite the remarkable clinical efficacy of chimeric antigen receptor (CAR) T cells in hematological malignancies, only a subset of patients achieve a durable complete response. Furthermore,...
Competing to offer a comprehensive genomic profiling service for solid or hematology oncology tumor samples is challenging, especially as panels increase in size and complexity. QIAGEN Clini...
Chimeric antigen receptor (CAR) T-cell therapy has been extremely successful in treating relapsed/refractory B-cell malignancies, with six CAR T-cell products now FDA approved. Unfortunately...
There are currently several different FDA approved radiopharmaceuticals being used in both large academic and small practice settings to accurately stage and identify local and metastatic pr...
Learning Objectives: 1. Classify the obstacles to successful manufacturing of antigen-specific T-cells in immunotherapy. 2. Highlight the effects of CD45RA+ subsets in expansion of antigen-s...
Effective cellular therapies for solid tumors remain elusive. Advances in gene editing and synthetic biology offer great potential for improving the safety and functionality of engineered ce...
Every patient is different and so is every tumor! The term “personalized oncology” today is largely associated with sequencing approaches. Current publications proof more and mor...
Brain cancer research stands to benefit from the perspectives, tools, and methodologies of non-traditional fields, such as mechanical engineering. Here, I will discuss our engineering-based...
Understanding the spatial organization of the immune response within tumors is crucial for developing effective cancer immunotherapies. In this seminar, we delve into the interactions betwee...
Nanovials are emerging as an accessible platform for performing single-cell functional screening leveraging standard instrumentation, such as flow cytometers and microfluidic single-cell seq...
The future of cancer care is contingent on better understanding of molecular, clinical, and outcome data. This can be achieved by leveraging collaborative affiliations and networks locally a...
![Anti-PRAME antibody [EPR20330]](https://d3bkbkx82g74b8.cloudfront.net/eyJidWNrZXQiOiJsYWJyb290cy1pbWFnZXMiLCJrZXkiOiJjb21wYW55X3Byb2R1Y3RfcHJvZmlsZV9pbWFnZV9mMzEwNTY4MGY1NmVmZjU3ZjZhMWRkZTU2M2Q4YjBmODZjMDJkNDE4XzMwMDA3MTg1ODEyLmpwZyIsImVkaXRzIjp7InRvRm9ybWF0IjoianBnIiwicmVzaXplIjp7IndpZHRoIjozMDAsImhlaWdodCI6MzAwLCJmaXQiOiJjb3ZlciIsInBvc2l0aW9uIjoiY2VudGVyIiwiYmFja2dyb3VuZCI6IiNmZmYifSwiZmxhdHRlbiI6eyJiYWNrZ3JvdW5kIjoiI2ZmZiJ9fX0=)
